During subgroup analysis , a more beneficial effect of magnesium supplementation was observed in diabetic subjects with hypomagnesaemia .
CONCLUSIONS Magnesium supplementation can produce a favourable effect on FPG , HDL , LDL , TG and SBP .
BACKGROUND Cardiovascular disorders remain the leading cause of death in type 2 diabetic patients .
In the present study , a systematic review and a meta- analysis of r and omised controlled trials ( RCTs ) were conducted aim ing to evaluate the effect of magnesium supplementation on  type 2 diabetes ( T2D ) associated cardiovascular risk factors in both diabetic and nondiabetic individuals .
Effects of extended-release niacin with laropiprant in high-risk patients.
BACKGROUND Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein ( LDL ) cholesterol level . Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein ( HDL ) cholesterol level , but its clinical efficacy and safety are uncertain . METHODS After a prer and omization run-in phase to st and ardize the background statin-based LDL cholesterol-lowering therapy and to establish participants ' ability to take extended-release niacin without clinical ly significant adverse effects , we r and omly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily . The primary outcome was the first major vascular event ( nonfatal myocardial infa rct ion , death from coronary causes , stroke , or arterial revascularization ) . RESULTS During a median follow-up period of 3.9 years , participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter ( 0.25 mmol per liter as measured in the central laboratory ) lower and an HDL cholesterol level that was an average of 6 mg per deciliter ( 0.16 mmol per liter ) higher than the levels in those assigned to placebo . Assignment to niacin-laropiprant , as compared with assignment to placebo , had no significant effect on the incidence of major vascular events ( 13.2 % and 13.7 % of participants with an event , respectively ; rate ratio , 0.96 ; 95 % confidence interval [ CI ] , 0.90 to 1.03 ; P=0.29 ) . Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious ( absolute excess as compared with placebo , 3.7 percentage points ; P<0.001 ) and with an increased incidence of diabetes diagnoses ( absolute excess , 1.3 percentage points ; P<0.001 ) , as well as increases in serious adverse events associated with the gastrointestinal system ( absolute excess , 1.0 percentage point ; P<0.001 ) , musculoskeletal system ( absolute excess , 0.7 percentage points ; P<0.001 ) , skin ( absolute excess , 0.3 percentage points ; P=0.003 ) , and unexpectedly , infection ( absolute excess , 1.4 percentage points ; P<0.001 ) and bleeding ( absolute excess , 0.7 percentage points ; P<0.001 ) . CONCLUSIONS Among participants with atherosclerotic vascular disease , the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events . ( Funded by Merck and others ; HPS2-THRIVE Clinical Trials.gov number , NCT00461630 . )
During subgroup analysis , a more beneficial effect of magnesium supplementation was observed in diabetic subjects with hypomagnesaemia .
CONCLUSIONS Magnesium supplementation can produce a favourable effect on FPG , HDL , LDL , TG and SBP .
BACKGROUND Cardiovascular disorders remain the leading cause of death in type 2 diabetic patients .
In the present study , a systematic review and a meta- analysis of r and omised controlled trials ( RCTs ) were conducted aim ing to evaluate the effect of magnesium supplementation on  type 2 diabetes ( T2D ) associated cardiovascular risk factors in both diabetic and nondiabetic individuals .